Alnylam says alleged 'stealing' was covered by RNAi agreements: Tekmira still confident
This article was originally published in Scrip
Executive Summary
Tekmira Pharmaceuticals has said that Alnylam's filing of an answer and counterclaim on 7 April to its recent US lawsuit alleging misappropriation of trade secrets "is an expected development in this litigation".